Cullinan oncology provides corporate update and reports first quarter 2022 financial results

Announced u.s. co-development and co-commercialization agreement for cln-081 with taiho pharmaceutical; updated cln-081 data accepted for oral presentation at the american society for clinical oncology (asco) meeting in june
CGEM Ratings Summary
CGEM Quant Ranking